Hara Isao, Miyake Hideaki, Yamanaka Kazuki, Hara Shoji, Kamidono Sadao
Department of Urology, Kobe University School of Medicine, Chuo-ku, Kobe 650-0017, Japan.
Oncol Rep. 2002 Nov-Dec;9(6):1379-83.
We examined whether serum levels of cathepsin D (CatD) and its density (CatD-D), which was determined by dividing the serum levels of CatD by the prostate volume, could be used as predictors of the progression and prognosis in patients with prostate cancer. Serum levels of CatD in 40 healthy controls, 70 patients with benign prostatic hypertrophy (BPH) and 80 patients with prostate cancer were measured by a sandwich enzyme immunoassay, and prostate volume was measured using transrectal ultrasonography. The mean levels of CatD and CatD-D in patients with prostate cancer were significantly higher than those in healthy controls and patients with BPH. Furthermore, the CatD and CatD-D levels in prostate cancer patients with metastasis were significantly elevated compared with those in patients without metastasis. Among patients who underwent radical prostatectomy, the levels of CatD and CatD-D in patients with pathologically organ-confined disease were significantly lower than in those with extraprostatic disease. However, the elevated levels of CatD and CatD-D were not significantly associated with the cause-specific survival in prostate cancer patients. These findings suggest that the elevation of CatD or CatD-D could be used as new predictors of disease progression, but not prognosis, in patients with prostate cancer.
我们研究了组织蛋白酶D（CatD）的血清水平及其密度（CatD-D，通过将CatD的血清水平除以前列腺体积来确定）是否可作为前列腺癌患者疾病进展和预后的预测指标。采用夹心酶免疫测定法测量了40名健康对照者、70名良性前列腺增生（BPH）患者和80名前列腺癌患者的CatD血清水平，并使用经直肠超声测量前列腺体积。前列腺癌患者的CatD和CatD-D平均水平显著高于健康对照者和BPH患者。此外，有转移的前列腺癌患者的CatD和CatD-D水平显著高于无转移患者。在接受根治性前列腺切除术的患者中，病理器官局限型疾病患者的CatD和CatD-D水平显著低于前列腺外疾病患者。然而，CatD和CatD-D水平升高与前列腺癌患者的病因特异性生存率无显著相关性。这些发现表明，CatD或CatD-D升高可作为前列腺癌患者疾病进展的新预测指标，但不能作为预后的预测指标。
